Aktienanalyse zu Tandem Diabetes Care Inc (TNDM)TNDMTandem Diabetes Care Inc

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tandem Diabetes Care Inc is currently priced at $16.24, which is below the average analyst price target of $20 to $40. However, the stock has a forward P/E ratio of 117.65, indicating high valuation concerns. Additionally, the RSI is at 47.66, suggesting the stock is neither overbought nor oversold. The main risk is the high debt-to-equity ratio of 465.90%, which could impact financial stability.

7 analysts cover TNDM: 1 rate it Buy, 5 Hold and 1 Sell. The average price target is 26.33.